Edition:
India

People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

4.76USD
13 Dec 2019
Change (% chg)

$-0.28 (-5.56%)
Prev Close
$5.04
Open
$4.92
Day's High
$5.18
Day's Low
$4.63
Volume
1,517,256
Avg. Vol
446,577
52-wk High
$16.80
52-wk Low
$2.27

Todisco, Joseph 

Mr. Joseph Todisco is a Senior Vice President, Specialty Commercial of the Company. Joe has leadership responsibility for Specialty and International, as well as continued responsibility for the Amneal-Impax integration process. Joe joined Amneal six years ago as the head of Corporate Development and has been an integral part of the management team that executed the Amneal-Impax business combination, as well as multiple other business development, licensing and M&A transactions. In addition to his role in Corporate Development, Joe held management oversight responsibility for Gemini Laboratories, building the company from inception to a highly profitable specialty pharmaceutical platform. Prior to joining Amneal, Joe spent more than five years leading Ranbaxy’s North American Commercial Strategy and Business Development, and held various leadership roles with Par Pharmaceuticals. Prior to working in the pharmaceutical industry, Joe was an investment banker for Oppenheimer & Co. and also worked in financial services for Marsh & McLennan Companies. Joe holds a bachelor’s degree in Economics from Georgetown University in Washington D.C. and an M.B.A. from Fordham Graduate School of Business in New York.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --